Health Canada lists Erelzi 25 mg etanercept shortage as Tier 3
Sandoz reports a manufacturing disruption affecting Erelzi 25 mg/0.5 mL prefilled syringes. The company estimates the shortage will end Feb. 12, 2027.
In this article & details
Health Canada classified a shortage of 25 mg/0.5 mL etanercept injection as Tier 3 on Nov. 12. Sandoz Canada reports a manufacturing disruption affecting Erelzi 25 mg prefilled syringes, DIN 02462877. Its Nov. 13 report lists an active shortage and an estimated end date of Feb. 12, 2027. Health Canada designation · Sandoz shortage report
The designation identifies the 25 mg syringe
Health Canada’s Drug Product Database identifies the affected presentation as a single-use prefilled syringe for subcutaneous injection. Erelzi is a biosimilar of etanercept, used for conditions including rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. Other Erelzi presentations include a 50 mg prefilled syringe and a 50 mg auto-injector. The federal designation specifies the 25 mg/0.5 mL presentation. Canadian product record · B.C. PharmaCare decision summary
Tier 3 signals a potentially serious supply impact
Health Canada uses Tier 3 for shortages that could have the greatest effect on the Canadian drug supply and health system. Its assessment considers how necessary the drug is and how readily supplies or alternatives can be found. The Canadian Rheumatology Association and Canadian Pharmacists Association were among the organizations represented in the etanercept assessment. Sandoz’s report is the source for its projected end date and later supply updates. Tier 3 criteria and committee · Latest manufacturer status
References
- Tier 3 drug shortages — Health Canada, Etanercept determination, Nov. 12, 2026
- Drug Shortage Report for ERELZI — Sandoz Canada Incorporated, Health Product Shortages Canada, Report 295430, updated Nov. 13, 2026
- Product information: ERELZI — Health Canada Drug Product Database, DIN 02462877
- Erelzi (etanercept): Drug decision summary — British Columbia PharmaCare, Background on strengths and approved indications
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.